Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis

This publication has 30 references indexed in Scilit:

• Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000
  Journal of Clinical Oncology, 2004
• Economics of the clinical management of lung cancer in France: an analysis using a Markov model
  British Journal of Cancer, 2004
• Management and Costs of Treating Lung Cancer Patients in a University Hospital
  PharmacoEconomics, 2004
• A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
  Cancer, 2003
• Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy
  JNCI Journal of the National Cancer Institute, 2002
• Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
  Cancer, 2002
• What are cancer patients willing to pay for prophylactic epoetin alfa?
  Cancer, 1998
• Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
  British Journal of Cancer, 1998
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
  Journal of Clinical Oncology, 1997
• Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced Anemia
  Annals of Pharmacotherapy, 1997